Schistosoma Haematobium Infections and Praziquantel

Learn more about:
Related Clinical Trial
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Schistosoma Haematobium Infections and Praziquantel

Official Title

Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel

Brief Summary

      The purpose of this study is to evaluate the impact of praziquantel for the treatment of
      Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.
    

Detailed Description

      A longitudinal study will be conducted to evaluate the impact of praziquantel for the
      treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in
      Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1
      year after treatment with a single dose of praziquantel 40mg/kg.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

cure rate

Secondary Outcome

 reduction in the intensity of infection by

Condition

Schistosomiasis

Intervention

praziquantel

Study Arms / Comparison Groups

 Praziguantel
Description:  tablet single dose

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

520

Start Date

August 2008

Completion Date

September 2012

Primary Completion Date

August 2012

Eligibility Criteria

        Inclusion Criteria:

          -  School children

        Exclusion Criteria:

          -  Taking praziquantel
      

Gender

All

Ages

6 Years - 15 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Sudan

Location Countries

Sudan

Administrative Informations


NCT ID

NCT01558336

Organization ID

Schistosmiasis


Responsible Party

Principal Investigator

Study Sponsor

University of Khartoum

Collaborators

 Hikma Pharmaceuticals LLC

Study Sponsor

, , 


Verification Date

January 2013